2 research outputs found
The low affinity A2B adenosine receptor enhances migratory and invasive capacity in vitro and angiogenesis in vivo of glioblastoma stem-like cells.
Glioblastoma (GBM) is the most common and deadlymalignant brain tumor,with
a median survival of 15 to 17 months for a patient. GBM contains a cellular
subpopulation known as GBM stem-like cells (GSCs) that persist in hypoxic
niches and are capable of infiltrating into healthy brain tissue. For this reason,
GSCs are considered one of the main culprits for GBM recurrence. A hypoxic
microenvironment increases extracellular adenosine levels, activating the low
affinity A2B adenosine receptor (A2BAR). Adenosine, through A2BAR, is capable of
modulating invasiveness. However, its role in the invasion/migration of hypoxic-
GSCs is still unknown. This study aims to understand the importance of A2BAR in
modulating themigratory/invasive capacity of GSCs under hypoxia. Data analysis
from The Cancer Genome Atlas (TCGA) program correlates A2BAR expression
with high-grade glioma and hypoxic necrotic areas. U87MG and primary culturederived
GSCs under hypoxic conditions (0.5% O2) increased A2BAR mRNA and
protein levels. As expected, the migratory and invasive capacity of GSCs
increased under hypoxia, which was counteracted by blocking A2BAR, through
the downregulation of MMP9 activity and epithelial–mesenchymal transition
marker expression. Finally, in a xenograft mouse model, we demonstrate that
treatment with MRS1754 did not affect the tumor volume but could decrease
blood vessel formation and VEGF expression. Our results suggest that
extracellular adenosine, through the activation of A2BAR, enhances the
migratory and invasive capacity of GSCs in vitro under hypoxic conditions.
Targeting A2BAR can be an effective therapy for GBM recurrence.post-print556 K
Cancer Stem Cell and Aggressiveness Traits Are Promoted by Stable Endothelin-Converting Enzyme-1c in Glioblastoma Cells
Glioblastoma (GBM) is the most common and aggressive type of brain tumor due to its elevated recurrence following treatments. This is mainly mediated by a subpopulation of cells with stemness traits termed glioblastoma stem-like cells (GSCs), which are extremely resistant to anti-neoplastic drugs. Thus, an advancement in the understanding of the molecular processes underlying GSC occurrence should contribute significantly towards progress in reducing aggressiveness. High levels of endothelin-converting enzyme-1 (ECE1), key for endothelin-1 (ET-1) peptide activation, have been linked to the malignant progression of GBM. There are four known isoforms of ECE1 that activate ET-1, which only differ in their cytoplasmic N-terminal sequences. Isoform ECE1c is phosphorylated at Ser-18 and Ser-20 by protein kinase CK2, which increases its stability and hence promotes aggressiveness traits in colon cancer cells. In order to study whether ECE1c exerts a malignant effect in GBM, we designed an ECE1c mutant by switching a putative ubiquitination lysine proximal to the phospho-serines Lys-6-to-Arg (i.e., K6R). This ECE1cK6R mutant was stably expressed in U87MG, T98G, and U251 GBM cells, and their behavior was compared to either mock or wild-type ECE1c-expressing clone cells. ECE1cK6R behaved as a highly stable protein in all cell lines, and its expression promoted self-renewal and the enrichment of a stem-like population characterized by enhanced neurospheroid formation, as well as increased expression of stem-like surface markers. These ECE1cK6R-derived GSC-like cells also displayed enhanced resistance to the GBM-related chemotherapy drugs temozolomide and gemcitabine and increased expression of the ABCG2 efflux pump. In addition, ECE1cK6R cells displayed enhanced metastasis-associated traits, such as the modulation of adhesion and the enhancement of cell migration and invasion. In conclusion, the acquisition of a GSC-like phenotype, together with heightened chemoresistance and invasiveness traits, allows us to suggest phospho-ECE1c as a novel marker for poor prognosis as well as a potential therapeutic target for GBM